ATRA, a currently used target drug for acute promyelocytic leukemia (APL), mechanically combines with the substrate-binding site of Pin1 to inhibit its activation in APL and breast cancer cells36. This evidence concerns the gene PIN1 and acute promyelocytic leukemia.